{
    "pmcid": "9288967",
    "qa_pairs": {
        "How much did the covalent nanobody mNb6(108FFY) increase in potency against authentic SARS-CoV-2 virus compared to its noncovalent counterpart?": [
            "41-fold increase",
            "10-fold increase",
            "25-fold increase",
            "5-fold increase"
        ],
        "What is the main advantage of using covalent nanobodies over traditional noncovalent nanobodies against SARS-CoV-2?": [
            "Covalent nanobodies form a permanent bond with the spike protein, increasing neutralization potency",
            "Covalent nanobodies are less expensive to produce",
            "Covalent nanobodies have a shorter duration of action",
            "Covalent nanobodies are more susceptible to viral escape"
        ],
        "What is the primary target for therapeutic interventions against SARS-CoV-2 as described in the paper?": [
            "The receptor-binding domain (RBD) of the spike protein",
            "The nucleocapsid protein of the virus",
            "The membrane protein of the virus",
            "The envelope protein of the virus"
        ],
        "Which SARS-CoV-2 variant required a different nanobody due to extensive mutations, according to the study?": [
            "Omicron",
            "Alpha",
            "Delta",
            "Lambda"
        ],
        "Which unnatural amino acid is incorporated into nanobodies to enable covalent binding to the SARS-CoV-2 spike protein?": [
            "Fluorine-substituted fluorosulfate-l-tyrosine (FFY)",
            "Methionine",
            "Serine",
            "Tryptophan"
        ]
    }
}